Search research articles
Contact Us
Filters
Showing results (21-30 of 257) with videos related to
Page
of 26
Sort By:
European Heart Journal
|
December 16, 2023
Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few
Giovanna Liuzzo, Carlo Patrono
European Heart Journal
|
August 6, 2021
A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes
Massimo Volpe, Carlo Patrono
European Heart Journal
|
November 18, 2021
Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?
Giovanna Liuzzo, Carlo Patrono
European Heart Journal
|
December 21, 2021
Quadruple combination of quarter doses of blood pressure-lowering agents: a string QUARTET in the symphony of hypertension management?
Massimo Volpe, Carlo Patrono
European Heart Journal
|
January 1, 2022
A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally
Giovanna Liuzzo, Carlo Patrono
European Heart Journal
|
March 4, 2021
A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19
Massimo Volpe, Carlo Patrono
European Heart Journal
|
February 21, 2022
In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure
Giovanna Liuzzo, Carlo Patrono
European Heart Journal
|
February 10, 2022
Age-independent benefits of blood pressure lowering: are they applicable to all patients?
Massimo Volpe, Carlo Patrono
Lancet (London, England)
|
October 17, 2008
Selective COX-2 inhibitors: where do we go from here?
Colin Baigent, Carlo Patrono
Journal of the American College of Cardiology
|
August 27, 2016
Aspirin and Cancer
Paola Patrignani, Carlo Patrono
Page
of 26
Search research articles
Search
Showing results (21-30 of 257) with videos related to
Sort By:
Page
of 26
European Heart Journal
|
December 16, 2023
Reducing cardiovascular outcomes with semaglutide: a metabolic route for a SELECT few
Giovanna Liuzzo, Carlo Patrono
European Heart Journal
|
August 6, 2021
A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes
Massimo Volpe, Carlo Patrono
European Heart Journal
|
November 18, 2021
Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?
Giovanna Liuzzo, Carlo Patrono
European Heart Journal
|
December 21, 2021
Quadruple combination of quarter doses of blood pressure-lowering agents: a string QUARTET in the symphony of hypertension management?
Massimo Volpe, Carlo Patrono
European Heart Journal
|
January 1, 2022
A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally
Giovanna Liuzzo, Carlo Patrono
European Heart Journal
|
March 4, 2021
A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19
Massimo Volpe, Carlo Patrono
European Heart Journal
|
February 21, 2022
In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure
Giovanna Liuzzo, Carlo Patrono
European Heart Journal
|
February 10, 2022
Age-independent benefits of blood pressure lowering: are they applicable to all patients?
Massimo Volpe, Carlo Patrono
Lancet (London, England)
|
October 17, 2008
Selective COX-2 inhibitors: where do we go from here?
Colin Baigent, Carlo Patrono
Journal of the American College of Cardiology
|
August 27, 2016
Aspirin and Cancer
Paola Patrignani, Carlo Patrono
Page
of 26